Comparative effectiveness, safety, and costs of rivaroxaban and warfarin treatment among morbidly obese patients with venous thromboembolism
AC Spyropoulos, V Ashton, YW Chen, B Wu… - Blood, 2018 - ashpublications.org
Background: Use of direct-acting oral anticoagulants (DOACs) in morbidly obese (BMI> 40
kg/m 2) patients for venous thromboembolism (VTE) treatment is not fully understood …
kg/m 2) patients for venous thromboembolism (VTE) treatment is not fully understood …
[HTML][HTML] Comparative Effectiveness, Safety, and Costs of Rivaroxaban and Warfarin Treatment Among Morbidly Obese Patients with Venous Thromboembolism
AC Spyropoulos, V Ashton, YW Chen, B Wu… - Blood, 2018 - Elsevier
Background: Use of direct-acting oral anticoagulants (DOACs) in morbidly obese (BMI> 40
kg/m 2) patients for venous thromboembolism (VTE) treatment is not fully understood …
kg/m 2) patients for venous thromboembolism (VTE) treatment is not fully understood …
Comparative Effectiveness, Safety, and Costs of Rivaroxaban and Warfarin Treatment Among Morbidly Obese Patients with Venous Thromboembolism
AC Spyropoulos, V Ashton, YW Chen, B Wu… - Blood, 2018 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Background: Use of direct-acting oral
anticoagulants (DOACs) in morbidly obese (BMI> 40 kg/m2) patients for venous …
anticoagulants (DOACs) in morbidly obese (BMI> 40 kg/m2) patients for venous …